Kathryn J. Smith

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

David W. Rusnak, Karen Affleck, Stuart Cockerill et al. · PubMed · 2001 · 297 citations

Potential Therapy, Tumor Biology, Oncology +18

Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions

Anna M.D. Watson, Gavin Lambert, Kathryn J. Smith et al. · Hypertension · 2003 · 88 citations

Heart Failure, Small Peptide, Cardiovascular Function +22

Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2

Stuart Cockerill, Colin Stubberfield, Jeremy N. Stables et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 79 citations · Full text

Medicinal Chemistry, Indazolylamino Quinazolines, Medicine +10

Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity

Richard Angell, Paul Bamborough, Jacky B. Buckton et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 72 citations · Full text

Medicinal Chemistry, Vivo Activity, Chemoprevention Strategy +11

Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines

Micheal D. Gaul, Yu Guo, Karen Affleck et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 57 citations · Full text

Medicinal Chemistry, Medicine, Rational Drug Design +7